Literature DB >> 22353852

Spinocerebellar ataxia type 31 exists in northeast China.

Yi Ouyang1, Zhiyi He, Lei Li, Xue Qin, Yinan Zhao, Liying Yuan.   

Abstract

Spinocerebellar ataxia type 31 (SCA31), is a recently defined subtype of autosomal dominant cerebellar ataxia (ADCA) characterized by late-onset pure cerebellar ataxia. SCA31 is common in Japan but whether or not it exists in other countries is still unclear. In this study, the authors describe a sporadic Chinese patient with SCA31. Although the cardinal clinical features, i.e., late-onset cerebellar ataxia and hearing impairment in our sporadic patient were similar to those described previously in Japan, mild axonal sensorimotor neuropathy was identified in our SCA31 patient, which is somewhat distinct from most prior reports of the disease. This is the first report of SCA31 in China; thus, extending the ethnic association beyond families of Japanese origin. In addition, our study suggests that the clinical features of SCA31 might be broader than previously thought.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22353852     DOI: 10.1016/j.jns.2012.02.005

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  3 in total

Review 1.  Mechanistic and Therapeutic Insights into Ataxic Disorders with Pentanucleotide Expansions.

Authors:  Nan Zhang; Tetsuo Ashizawa
Journal:  Cells       Date:  2022-05-06       Impact factor: 7.666

2.  Distinctive features of degenerating Purkinje cells in spinocerebellar ataxia type 31.

Authors:  Kunihiro Yoshida; Mika Asakawa; Emi Suzuki-Kouyama; Kenichi Tabata; Masayuki Shintaku; Shu-Ichi Ikeda; Kiyomitsu Oyanagi
Journal:  Neuropathology       Date:  2013-12-17       Impact factor: 1.906

Review 3.  Molecular Mechanisms in Pentanucleotide Repeat Diseases.

Authors:  Joana R Loureiro; Ana F Castro; Ana S Figueiredo; Isabel Silveira
Journal:  Cells       Date:  2022-01-08       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.